Appetite Loss, Cachexia; Cancer, Cannabis, Morbidity, Mortality, Neoplasms Pancreatic, Palliative Medicine
Conditions
Brief summary
Cannabinoids are known to increase appetite, but THC components have psychogenic properties too. CBD is the main component in the plant, and have only minimal psychogenic effects. The aim was to test the appetite stimulating effects of CBD in patients with pancreatic cancer in palliative treatment.
Detailed description
Randomization of consecutive patients who wanted to participate to a daily dose of CBD or not as a supplement to the standard treatment.
Interventions
DRUGTHC and CBD Mixture
Individually titrated doses on daily basis
Sponsors
Jens Rikardt Andersen
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult, palliative pancreatic cancer diagnosis, weight loss \> 5%, understand and read Danish.
Exclusion criteria
* Regular use of cannabis, psychiatric disorders, alcohol abuse, life expectancy \< 6 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Energy and protein intake | The outcome measure will be assessed at day 0 and at week 4 | Dietary history (% of estimated needs - NRS 2002) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Appetite 1 | The outcome measure will be assessed at day 0 and at week 4 | VAS (cm on 10 cm scale) |
| Appetite 2 | The outcome measure will be assessed at day 0 and at week 4 | Dietary history (VAS (cm on 10 cm scale)) |
| Appetite 3 | The outcome measure will be assessed at day 0 and at week 4 | EORTC QLQ-C30 (score, standard for the Quality of Life entity) |
| Appetite 4 | The outcome measure will be assessed at day 0 and at week 4 | EORTC QLQ-PAN26 (score, standard for the Quality of Life entity) |
| Quality of life 1 | The outcome measure will be assessed at day 0 and at week 4 | EORTC QLQ-C30 (score, standard for the Quality of Life entity) |
| Lean body mass | The outcome measure will be assessed at day 0 and at week 4 | Bioimpedance (% of body weight, kg) |
| Quality of life 3 | The outcome measure will be assessed at day 0 and at week 4 | VAS (VAS (cm on 10 cm scale)) |
| Pain 1 | The outcome measure will be assessed at day 0 and at week 4 | EORTC QLQ-C30 (score, standard for the Quality of Life entity) |
| Pain 2 | The outcome measure will be assessed at day 0 and at week 4 | EORTC QLQ-PAN26 (score, standard for the Quality of Life entity) |
| Pain 3 | The outcome measure will be assessed at day 0 and at week 4 | VAS (VAS (cm on 10 cm scale)) |
| Mortality (8 weeks) | 8 weeks | Patient records, national register |
| Quality of life 2 | The outcome measure will be assessed at day 0 and at week 4 | EORTC QLQ-PAN26 (score, standard for the Quality of Life entity) |
Countries
Denmark
Outcome results
None listed